4D Molecular Therapeutics
FDMT
100 hedge funds and large institutions have $745M invested in 4D Molecular Therapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 19 reducing their positions, and 16 closing their positions.
153% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 19
43% more capital invested
Capital invested by funds: $522M → $745M (+$223M)
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
6.97% more ownership
Funds ownership: 91.5% → 98.47% (+7%)
6% more funds holding
Funds holding: 94 → 100 (+6)
31% less call options, than puts
Call options by funds: $1.3M | Put options by funds: $1.89M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$56.5M |
| 2 |
VA
VR Adviser
New York
|
+$55.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$17.7M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$15.6M |
| 5 |
DM
Deerfield Management
New York
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$8.59M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$5.05M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.61M |
| 4 |
Morgan Stanley
New York
|
-$3.21M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$2.54M |
FDMT Hedge Fund Activity: Q2 2023 in Review
100 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2023, worth a combined $745M — up 43% from $522M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FDMT positions and 16 closed out — a net gain of 6 holders — while 48 added to existing stakes and 19 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $56.5M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $8.59M sold.
- 100 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2023, up from 94 in Q1 2023.
- Funds reported $745M of 4D Molecular Therapeutics stock for Q2 2023, up 43% quarter-over-quarter.
- 22 funds opened new 4D Molecular Therapeutics positions in Q2 2023 and 16 closed out, a net change of +6 holders.
- The largest 4D Molecular Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $56.5M added.
- The largest 4D Molecular Therapeutics seller in Q2 2023 was Octagon Capital Advisors, an estimated $8.59M sold.
Based on aggregated 13F filings for Q2 2023.